I've been seeing articles like this piece. It says a bi-monthly injection of cabotegravir provided better protection for PrEP than current daily pills. That's great I suppose, but then we get to these 2 points.
The finding — in which a third fewer people became infected on cabotegravir compared with the other drugs...
I thought there were so very few failures on current PrEP meds. What happened? How could anything be more effective than what they've touted for Truvada?
Then, this piece mentioned no women, only men & transgender women. There have been studies on this med & women. But, most like this study do not include those born female.
While I hope meds like this progress well. I have questions about the alleged efficacy & why women aren't more prevalent in most PrEP studies. If they're going to keep pushing this approach, they can't leave out half the population.
Cya...
No comments:
Post a Comment